Cancer Communications最新文献

{"title":"Preoperative Chemoradiotherapy versus Chemotherapy for Locally Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma: A Phase III Randomized Controlled Trial from China.","authors":"Xiaowen Liu, Jiejie Jin, Menglong Zhou, Ye Zhou, Hong Cai, Hua Huang, Min Yan, Zhongyin Yang, Runhua Feng, Qi Lu, Hao Ding, Hongtao Xu, Xuexiao Liu, Guichao Li, Hui Zhu, Weiqi Sheng, Xiujiang Yang, Zhen Zhang, Yanong Wang","doi":"10.34133/cancomm.0006","DOIUrl":"10.34133/cancomm.0006","url":null,"abstract":"<p><p><b>Background:</b> The prognostic superiority of preoperative chemoradiotherapy (pre-CRT) over preoperative chemotherapy (pre-CT) in patients with locally advanced gastric cancer remains controversial. Herein, we evaluated the efficacy and safety of pre-CRT relative to those of pre-CT in this cohort. <b>Methods:</b> This open-label, phase III, randomized controlled trial was conducted at 4 medical centers in China. Eligible patients with locally advanced gastric cancer or esophagogastric junction adenocarcinoma were randomly assigned (1:1) to receive either 3 cycles of oxaliplatin and S-1 (SOX), followed by surgery and 3 postoperative cycles of SOX (pre-CT), or 1 cycle of SOX, followed by concurrent chemoradiotherapy, a second cycle of SOX, surgery, and 3 postoperative cycles of SOX (pre-CRT). The primary endpoint was 3-year disease-free survival (DFS). Secondary endpoints included 3-year overall survival (OS), R0 resection rate, pathological complete response (pCR) rate, treatment-related toxicity, and postoperative complications. <b>Results:</b> Due to premature trial termination, only 204 patients were enrolled, and an efficacy analysis was conducted on 194 eligible patients. The baseline characteristics were well balanced between the 2 groups. The DFS and OS were indistinguishable between the 2 groups. The 3-year DFS rates were 53.6% in the pre-CRT group and 53.9% in the pre-CT group [hazard ratio (HR), 1.02; 95% confidence interval (CI), 0.70 to 1.50; log-rank <i>P</i> = 0.913]. The 3-year OS rates were 62.8% in the pre-CRT group and 60.5% in the pre-CT group (HR, 0.97; 95% CI, 0.63 to 1.47; log-rank <i>P</i> = 0.874). The R0 resection rates were 81.0% and 74.5% in the pre-CRT and pre-CT groups, respectively. Additionally, the pCR rate was higher in the pre-CRT group (12.0%) than in the pre-CT group (2.1%). Treatment-related toxic effects were comparable between the 2 groups. <b>Conclusion:</b> This trial did not demonstrate a survival advantage for pre-CRT over pre-CT in patients with locally advanced gastric or gastroesophageal adenocarcinoma.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0006"},"PeriodicalIF":24.9,"publicationDate":"2026-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12857758/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment of Metastatic Cancer by Conferring Immunogenicity to the Apoptotic Bodies of the Primary Tumor.","authors":"So-Jung Kim, Hae-Bin Park, Eun-Koung An, Dayoung Ryu, Da Young Kim, Daeun Lim, Wei Zhang, Xiaoyan Zhang, Jianqing Xu, Peter Chang-Whan Lee, Jun-O Jin","doi":"10.34133/cancomm.0001","DOIUrl":"10.34133/cancomm.0001","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0001"},"PeriodicalIF":24.9,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12856765/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103920","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endopharyngeal Ultrasound-Guided Transpharyngeal Needle Aspiration for Confirming Retropharyngeal Lymph Nodes' Metastasis among Nasopharyngeal Carcinoma Patients.","authors":"Chuanbo Xie, Long-Jun He, Wencheng Tan, Jindong Xie, Yin Li, Lizhi Liu, Guangyu Luo, Kunhao Bai, Hai-Qiang Mai, Guokai Feng, Jun Ma, Jian-Jun Li","doi":"10.34133/cancomm.0004","DOIUrl":"10.34133/cancomm.0004","url":null,"abstract":"","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0004"},"PeriodicalIF":24.9,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12857757/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Hypoxia-Induced Osteopontin-Positive Glioma-Associated Macrophages Facilitate Glioma Mesenchymal Transition via NF-κB Pathway Activation.","authors":"Jingchen Yang, Xuejing Li, Xiaoxue Zhu, Ziwei Li, Xiaoyong Chen, Ruoyu Huang, Mingchen Yu, Bo Han, Tao Jiang, Chuanbao Zhang, Xing Liu","doi":"10.34133/cancomm.0007","DOIUrl":"10.34133/cancomm.0007","url":null,"abstract":"<p><p><b>Background:</b> Hypoxia is a prevalent, characteristic feature of the tumor microenvironment (TME) in glioblastomas (GBMs). As dominant immune cells within the TME, glioma-associated macrophages (GAMs) crucially regulate tumor progression. A comprehensive understanding of the effect of hypoxia on the behavior of GAMs is essential for elucidating the immune landscape and developing innovative therapeutic strategies. This study aimed to elucidate the mechanisms by which GAMs facilitate GBM progression under hypoxic conditions. <b>Methods:</b> Transcriptome sequencing, single-cell RNA sequencing, and spatial transcriptomic analyses were performed to explore the correlation between hypoxia and GAMs. Clinical samples were used to validate the findings. The underlying molecular mechanisms were examined via chromatin immunoprecipitation, quantitative real-time polymerase chain reaction, Western blotting analysis, and immunofluorescence assays. The therapeutic effectiveness was assessed via the use of in vivo models. <b>Results:</b> A subset of GAMs with elevated osteopontin (OPN) expression accumulates in response to hypoxic stimulation. Hypoxia induces OPN expression in macrophages via the histone 3 lysine 4 trimethylation-WD40 repeat-containing protein 5 (H3K4me3-WDR5) epigenetic axis. These OPN-positive GAMs (OPN⁺ GAMs) enhance the mesenchymal transition in GBMs by secreting OPN into the TME. Mechanistically, OPN activates nuclear factor κB (NF-κB) signaling through cluster of differentiation 44 (CD44), subsequently leading to increased programmed cell death ligand 1 (PD-L1) expression. The inhibition of OPN increased GBM sensitivity to temozolomide (TMZ) in orthotopic models. <b>Conclusions:</b> This study revealed the potential mechanism by which hypoxia-induced OPN⁺ GAMs promote the mesenchymal transition in GBM cells and demonstrated the therapeutic potential of targeting OPN to enhance TMZ treatment effectiveness.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0007"},"PeriodicalIF":24.9,"publicationDate":"2026-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12857759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Spatiotemporal Heterogeneity of Tumor-Associated Stromal Cells: Reprogramming Plasticity to Unlock Precision Cancer Immunotherapy.","authors":"Yingying Lv, Tingfei Duan, Jinling Song, Shutong Liu, Zhaokai Zhou, Yuhao Ba, Siyuan Weng, Anning Zuo, Hui Xu, Peng Luo, Quan Cheng, Chuhan Zhang, Jingyuan Ning, Yukang Chen, Yuyuan Zhang, Zaoqu Liu, Xinwei Han","doi":"10.34133/cancomm.0002","DOIUrl":"10.34133/cancomm.0002","url":null,"abstract":"<p><p>Tumor-associated stromal cells (TASCs) are key architects of the tumor microenvironment (TME), playing a vital role in tumor development, metastasis, and therapeutic response. Their spatiotemporal heterogeneity, characterized by dynamic phenotypic plasticity, diverse cellular subtypes, and distinct spatial distributions, offers profound insights into tumor behavior and paves the way for innovative therapy development. In particular, stromal-immune interactions reveal the powerful capacity of TASCs to shape the immune landscape, highlighting their potential as targets in immunotherapy. Despite growing evidence in functional diversity, precise mechanisms underlying the temporal evolution and spatial organization of TASCs remain elusive, impeding clinical translation. This review delved into the molecular signatures and functional states of TASCs, emphasizing their roles in tumor dynamics and therapeutic resistance. We also discussed innovative strategies targeting the plasticity of TASCs to reverse immune evasion and potentiate immune-mediated tumor eradication. Future studies should prioritize identifying spatially resolved and mechanically defined biomarkers with multi-omics and machine learning approaches, enabling a comprehensive understanding of TASCs to bridge the gap from bench to bedside.</p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"46 ","pages":"0002"},"PeriodicalIF":24.9,"publicationDate":"2026-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12857762/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146103882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover Image, Volume 45, Issue 12","authors":"Xiaoting Zhang,&nbsp;Na Qin,&nbsp;Fenfen Ji,&nbsp;Hao Su,&nbsp;Haiyun Shang,&nbsp;Hongyan Chen,&nbsp;Dan Huang,&nbsp;Qing Li,&nbsp;Jing Ren,&nbsp;Weixin Liu,&nbsp;Yifei Wang,&nbsp;Wei Kang,&nbsp;Jiabin Wu,&nbsp;Chi-Chun Wong,&nbsp;Zongwei Cai,&nbsp;Matthew Tak Vai Chan,&nbsp;William Ka Kei Wu,&nbsp;Jun Yu,&nbsp;Huarong Chen","doi":"10.1002/cac2.70084","DOIUrl":"https://doi.org/10.1002/cac2.70084","url":null,"abstract":"<p>The cover image is based on the article <i>RNA m¹A methyltransferase TRMT61A promotes colorectal tumorigenesis by enhancing</i> ONECUT2 <i>mRNA stability and is a potential therapeutic target</i> by Huarong Chen et al., https://doi.org/10.1002/cac2.70070.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 12","pages":""},"PeriodicalIF":24.9,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover Image, Volume 45, Issue 12","authors":"Nicole C. Riedel,&nbsp;Carolin Walter,&nbsp;Flavia W. de Faria,&nbsp;Lea Altendorf,&nbsp;Paula Aust,&nbsp;Carolin Göbel,&nbsp;Archana Verma,&nbsp;Annika Ballast,&nbsp;Ivan Bedzhov,&nbsp;Rajanya Roy,&nbsp;Daniel Münter,&nbsp;Erik Schüftan,&nbsp;Thomas K. Albert,&nbsp;Claudia Rössig,&nbsp;Pascal Johann,&nbsp;Barbara von Zezschwitz,&nbsp;Sarah Sandmann,&nbsp;Julian Varghese,&nbsp;Christian Thomas,&nbsp;Ulrich Schüller,&nbsp;Jan M. Bruder,&nbsp;Kornelius Kerl","doi":"10.1002/cac2.70085","DOIUrl":"https://doi.org/10.1002/cac2.70085","url":null,"abstract":"<p>The cover image is based on the article <i>In vivo intratumoral heterogeneity in a dish: scalable forebrain organoid models of embryonal brain tumors for high-throughput personalized drug discovery</i> by Nicole C. Riedel et al., \u0000https://doi.org/10.1002/cac2.70074. \u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 12","pages":""},"PeriodicalIF":24.9,"publicationDate":"2025-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.70085","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145848406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-omics profiling identified two epithelioid sarcoma molecular subtypes with distinct signaling and immune characteristics","authors":"Carine Ngo,&nbsp;Léo Colmet-Daage,&nbsp;Julien Vibert,&nbsp;Clémence Hénon,&nbsp;Daniel Pissaloux,&nbsp;Alexander Valent,&nbsp;Jia Xiang Jin,&nbsp;Riwan Brillet,&nbsp;Julien Masliah-Planchon,&nbsp;Gaëlle Pierron,&nbsp;Ludovic Lacroix,&nbsp;Etienne Rouleau,&nbsp;Cyril Roussel-Simonin,&nbsp;Lilian Lecorgne,&nbsp;Clémence Astier,&nbsp;Marlène Garrido,&nbsp;Rastislav Bahleda,&nbsp;Benjamin Verret,&nbsp;Axel Le Cesne,&nbsp;Charles Honore,&nbsp;Matthieu Faron,&nbsp;Wolf Herman Fridman,&nbsp;Catherine Sautès-Fridman,&nbsp;Jean-Michel Coindre,&nbsp;Jean-Yves Scoazec,&nbsp;Joshua J Waterfall,&nbsp;Franck Bourdeaut,&nbsp;Thomas G. P. Grünewald,&nbsp;Jean-Yves Blay,&nbsp;Franck Tirode,&nbsp;Sophie Postel-Vinay","doi":"10.1002/cac2.70077","DOIUrl":"10.1002/cac2.70077","url":null,"abstract":"&lt;p&gt;Epithelioid sarcoma (EpS) is an aggressive soft tissue sarcoma characterized by switch/sucrose non-fermentable (SWI/SNF)-related matrix-associated actin-dependent regulator of chromatin subfamily B member 1 (SMARCB1) loss [&lt;span&gt;1&lt;/span&gt;]. Conventionally, EpS is histologically classified as either distal or proximal subtype, each exhibiting distinct clinical behaviors; these sometimes co-exist as “hybrid” EpS [&lt;span&gt;2, 3&lt;/span&gt;]. Differential diagnosis from other SMARCB1-deficient tumors, such as extracranial extrarenal rhabdoid tumors (EERTs), can be challenging [&lt;span&gt;4&lt;/span&gt;]. Beyond phenotypic diversity, EpS molecular heterogeneity remains poorly understood. To address this, we aimed to build a molecular classification and explore inter- and intra-tumor heterogeneity, using multi-omics profiling.&lt;/p&gt;&lt;p&gt;We profiled 33 EpSs and 3 EERTs using whole-exome sequencing (WES), DNA methylation, and bulk RNA-sequencing (RNA-seq); single-cell RNA-sequencing (scRNA-seq) and 10x Genomics Visium spatial transcriptomics were performed on 8 and 4 EpSs, respectively (Figure 1A, Supplementary Materials and Methods). Cases were reviewed by two senior pathologists and classified by histology (14 distal, 14 proximal, 5 hybrid EpSs) (Supplementary Figure S1, Supplementary Tables S1-S2).&lt;/p&gt;&lt;p&gt;Unsupervised RNA-seq clustering identified two EpS transcriptomic subtypes (Figure 1B): (i) distal-like (&lt;i&gt;n&lt;/i&gt; = 20) — including all distal EpS, 2 proximal and 4 hybrid EpSs — enriched in cell adhesion, circulatory system development genes and extracellular matrix; (ii) proximal-like (&lt;i&gt;n&lt;/i&gt; = 13) — comprising 12 proximal and 1 hybrid EpSs — enriched in synapse organization, response to wounding and macrophage activation (Supplementary Figure S2A, Supplementary Table S3). Gene set enrichment analysis revealed a significant enrichment in epithelial-mesenchymal transition (EMT) and ultraviolet response in distal-like EpS compared to proximal-like EpS (normalized enrichment score = 1.80 and 1.66, respectively; false discovery rate &lt; 25%; &lt;i&gt;p&lt;/i&gt; &lt; 0.05) (Supplementary Figure S2B, Supplementary Table S4).&lt;/p&gt;&lt;p&gt;We explored mechanisms of SMARCB1 loss in 31 EpSs and 3 EERTs, using WES, targeted next-generation sequencing, single-nucleotide polymorphism array, shallow whole-genome sequencing, DNA methylation and fluorescence in situ hybridization – depending on material availability (Supplementary Figure S3A, Supplementary Table S5). Biallelic &lt;i&gt;SMARCB1&lt;/i&gt; inactivation was identified in 16 (51.6%) of 31 EpSs (mostly homozygous deletions), without germline &lt;i&gt;SMARCB1&lt;/i&gt; alteration. Heterozygous loss-of-function alterations were found in 14/31 (45.2%) EpSs. &lt;i&gt;SMARCB1&lt;/i&gt; alteration types were similar across EpS transcriptomic subtypes and unrelated to &lt;i&gt;SMARCB1&lt;/i&gt; mRNA levels (Supplementary Figure S3B-D).&lt;/p&gt;&lt;p&gt;Recurrent alterations, excluding &lt;i&gt;SMARCB1&lt;/i&gt;, occurred in up to13% of EpSs (Supplementary Figure S3A, Supplementary Tables S6-S7). Median tumor mutatio","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 12","pages":"1760-1766"},"PeriodicalIF":24.9,"publicationDate":"2025-11-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12728484/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145630218","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anbenitamab in combination with chemotherapy in patients with HER2-positive gastric or gastroesophageal junction carcinoma who failed previous therapy containing trastuzumab: a multicenter, phase II study (KC-WISE 01)","authors":"Chuanhua Zhao,&nbsp;Jun Zhao,&nbsp;Yigui Chen,&nbsp;Bo Liu,&nbsp;Yangfeng Du,&nbsp;Chenglin Li,&nbsp;Jingdong Zhang,&nbsp;Mudan Yang,&nbsp;Ying Liu,&nbsp;Yuxian Bai,&nbsp;Suyi Li,&nbsp;Ruixing Zhang,&nbsp;Fangling Ning,&nbsp;Yanping Liu,&nbsp;Kai Zou,&nbsp;Qi Zhang,&nbsp;Yijiao Xie,&nbsp;Yuping An,&nbsp;Jianming Xu","doi":"10.1002/cac2.70080","DOIUrl":"10.1002/cac2.70080","url":null,"abstract":"&lt;p&gt;In 2022, gastric cancer (GC) ranked as the fifth most common cancer and the third leading cause of cancer death in China, with 358,672 new cases and 260,372 deaths, accounting for 37.0% and 39.4% of global cases, respectively [&lt;span&gt;1&lt;/span&gt;]. Previous studies have shown that 25.9% and 36.5% of GC patients in China were diagnosed at stages III and IV, respectively, with 5-year overall survival (OS) rates of 33.0% for stage III and 5.5% for stage IV [&lt;span&gt;2, 3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;A previous study reported that human epidermal growth factor receptor 2 (HER2) positivity was found in 8.8% of Chinese patients with gastric adenocarcinoma [&lt;span&gt;4&lt;/span&gt;]. Building on the ToGA trial [&lt;span&gt;5&lt;/span&gt;], which established trastuzumab plus chemotherapy as the standard first-line treatment for HER2-positive GC, the KEYNOTE-811 trial [&lt;span&gt;6&lt;/span&gt;] demonstrated superior progression-free survival (PFS) combined with immune checkpoint inhibitors, establishing this regimen as the current standard of care. Recent interim-analysis of the DESTINY-Gastric04 trial revealed that trastuzumab deruxtecan significantly improved overall survival compared to chemotherapy-based regimen in patients with HER2-positive gastric/gastroesophageal junction (GC/GEJ) carcinoma, leading to its establishment as second-line therapy [&lt;span&gt;7&lt;/span&gt;]. Furthermore, zanidatamab, a HER2-targeted bispecific antibody against extracellular domains (ECDs) 2 and 4, has shown promising efficacy as both a monotherapy and in combination with chemotherapy for HER2-overexpressing GC in the second-line setting [&lt;span&gt;8&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Anbenitamab, also known as SYS6092 (KN026), is a bispecific antibody that simultaneously binds to two distinct HER2 epitopes, the same extracellular domains targeted by trastuzumab (domain IV) and pertuzumab (domain II) [&lt;span&gt;9&lt;/span&gt;]. Here, we present the results of a phase II study (NCT05427383) evaluating the safety and efficacy of anbenitamab plus chemotherapy in patients with HER2-positive advanced GC who failed previous therapy containing trastuzumab. Patients with locally advanced or metastatic HER2-positive GC/GEJ carcinoma who failed previous therapy containing trastuzumab were assigned to receive anbenitamab (30 mg/kg, Day 1, every 3 weeks [Q3W]) plus paclitaxel (175 mg/m&lt;sup&gt;2&lt;/sup&gt;, Day 1, Q3W) or irinotecan (125 mg/m&lt;sup&gt;2&lt;/sup&gt;, Day 1 and Day 8, Q3W) at investigators' discretion based on previous treatment. Full methodology is detailed in the Supplementary Materials.&lt;/p&gt;&lt;p&gt;Between April 7, 2022, and January 12, 2023, 39 patients were enrolled across 19 hospitals in China (Supplementary Table S1) and were assigned to receive either anbenitamab plus paclitaxel (&lt;i&gt;n&lt;/i&gt; = 20) or anbenitamab plus irinotecan (&lt;i&gt;n&lt;/i&gt; = 19; Supplementary Figure S1). Baseline patient characteristics are detailed in Supplementary Table S2. Eastern Cooperative Oncology Group performance status (ECOG PS) scores of 0 and 1 were reported in 7 (17.9%) and 32 (82.1%) patients, respect","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 12","pages":"1755-1759"},"PeriodicalIF":24.9,"publicationDate":"2025-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12728473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145581732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cover Image, Volume 45, Issue 11","authors":"Jingbo Fu,&nbsp;Yanping Wei,&nbsp;Yun Yang,&nbsp;Xinwei Yang,&nbsp;Tao Ouyang,&nbsp;Xianming Wang,&nbsp;Shuzhen Chen,&nbsp;Zenglin Liu,&nbsp;Yu Su,&nbsp;Jing Fu,&nbsp;Miao Yu,&nbsp;Haihua Qian,&nbsp;Hao Song,&nbsp;Shuo Xu,&nbsp;Ru Zhao,&nbsp;Xue Jiang,&nbsp;Yunfei Huo,&nbsp;Man Zhang,&nbsp;Pinhua Yang,&nbsp;Zhao Yang,&nbsp;Kui Wang,&nbsp;Liang Li,&nbsp;Hongyang Wang","doi":"10.1002/cac2.70082","DOIUrl":"https://doi.org/10.1002/cac2.70082","url":null,"abstract":"<p>The cover image is based on the article <i>Intranuclear paraspeckle-circular RNA TACC3 assembly forms RNA-DNA hybrids to facilitate MASH-related hepatocellular carcinoma growth in an m⁶A-dependent manner</i> by Hongyang Wang et al., https://doi.org/10.1002/cac2.70061.\u0000\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure></p>","PeriodicalId":9495,"journal":{"name":"Cancer Communications","volume":"45 11","pages":""},"PeriodicalIF":24.9,"publicationDate":"2025-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cac2.70082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145547160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}